Literature DB >> 2446066

Serotonin and preactivated platelets in essential hypertension.

F R Bühler1, R Amstein, N Fetkovska.   

Abstract

In patients with essential hypertension, an activated platelet serotonin-induced vasoconstrictor axis can be postulated. Platelets from hypertensive patients have a shortened half-life, and turnover of serotonin is increased. Vasoconstriction may be produced through activation of 5-HT2 receptors secondary to high wall concentrations of serotonin released from "activated" platelets. The pharmacotherapeutic relevance of this pathophysiological chain of events can be tested with the 5-HT2-receptor blocker ketanserin, but the drug's alpha 1-blocking activity has to be taken into account. Ketanserin lowers blood pressure effectively and to a greater extent in older patients. This points to an age-linked mode of action, possibly related to greater endothelial and blood vessel damage with older age.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446066

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels.

Authors:  Charles P Mercado; Fusun Kilic
Journal:  Mol Interv       Date:  2010-08

2.  Shape change of human blood platelets: reliable and fast detection by quasi-elastic light scattering.

Authors:  E Spurej; O Glatter; G Pfeiler
Journal:  Experientia       Date:  1992-01-15

Review 3.  Ageing, serotonin and ketanserin.

Authors:  A Breckenridge
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Effects of ketanserin on left ventricular hypertrophy in hypertensive patients.

Authors:  C Cobo; L Alcocer; A Chávez
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

5.  Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression.

Authors:  H Fujisaki; H Ito; Y Hirata; M Tanaka; M Hata; M Lin; S Adachi; H Akimoto; F Marumo; M Hiroe
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.